Phospho-PLD1 (T147) Antibody

What is Phospho-PLD1 (T147) Antibody and what does it detect?

Phospho-PLD1 (T147) Antibody is a rabbit polyclonal antibody that specifically recognizes Phospholipase D1 (PLD1) only when phosphorylated at threonine 147. The antibody detects endogenous levels of PLD1 when this specific residue is phosphorylated, making it valuable for studying this post-translational modification . PLD1 functions as a phospholipase selective for phosphatidylcholine and plays critical roles in multiple cellular pathways including signal transduction, membrane trafficking, and mitosis regulation .

The specificity of this antibody derives from its creation using synthesized phospho-peptides around the phosphorylation site of human PC-PLD1 (phospho Thr147) . Through affinity purification techniques, non-phospho specific antibodies are removed to ensure selective detection of the phosphorylated form .

What applications is Phospho-PLD1 (T147) Antibody suitable for?

Phospho-PLD1 (T147) antibodies have been validated for multiple research applications with specific recommended dilution ranges:

When using this antibody for Western blotting, researchers should optimize protein loading to ensure detection of relatively low abundance phospho-proteins . The antibody works effectively with standard ECL detection systems when used with appropriate HRP-conjugated secondary antibodies.

What species reactivity does the Phospho-PLD1 (T147) Antibody have?

The Phospho-PLD1 (T147) antibody demonstrates cross-reactivity with multiple species, making it suitable for comparative studies:

This broad reactivity results from the high conservation of the T147 phosphorylation site and surrounding amino acid sequences across mammalian species . When planning experiments with novel cell lines or tissues, initial validation is still recommended despite this cross-reactivity profile.

What is the importance of the T147 phosphorylation site in PLD1?

The T147 phosphorylation site serves as a critical regulatory node in PLD1 function. Research has demonstrated that this site is essential for proper PLD1 activity in several cellular processes, particularly in regulated exocytosis . Phosphorylation at this position appears to function as a molecular switch that modulates PLD1 activation.

Mutation studies provide compelling evidence for the functional significance of T147 phosphorylation. When the T147 residue is replaced with alanine (T147A) to prevent phosphorylation, PLD1 activity and associated secretory functions are significantly impaired . Conversely, phospho-mimetic mutations (T147D and T147E) result in enhanced PLD1 activation and slightly higher levels of regulated secretion .

This phosphorylation site lies within consensus sequences for multiple kinases, including protein kinase C (PKC) and ribosomal S6 kinase (RSK2), suggesting integration of diverse signaling pathways through this single modification .

How should Phospho-PLD1 (T147) Antibody be stored and handled?

Proper storage and handling of phospho-specific antibodies is critical for maintaining sensitivity and specificity:

The antibody is typically provided at a concentration of 1 mg/mL, allowing for appropriate dilution for various applications . When preparing working solutions, use fresh, sterile buffers and consider adding protease inhibitors if extended storage is necessary.

What positive and negative controls should be included when using this antibody?

Including appropriate controls is essential for interpreting results with phospho-specific antibodies:

Positive Controls:

• Lysates from cells stimulated with agents known to increase T147 phosphorylation (e.g., potassium stimulation in neuroendocrine cells)

• Recombinant phosphorylated PLD1 protein (if available)

• Lysates from cells expressing phospho-mimetic PLD1 mutants (T147D or T147E)

Negative Controls:

• Unstimulated cell lysates

• Lysates from cells expressing phosphorylation-deficient PLD1 (T147A)

• Lysates from cells treated with phosphatase

• Lysates from cells treated with RSK2 inhibitor BI-D1870, which has been shown to block T147 phosphorylation

• Primary antibody omission control

Including these controls helps verify signal specificity and provides benchmarks for interpreting experimental results across different conditions.

How can Western blot protocols be optimized for detecting phospho-PLD1 (T147)?

Detecting phosphorylated proteins requires specific protocol optimizations:

• Sample preparation:

  • Extract proteins in buffer containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and phosphatase inhibitor cocktails)

  • Maintain samples at 4°C throughout processing

  • Consider using direct lysis in SDS sample buffer for immediate denaturation

• Gel electrophoresis:

  • Use freshly prepared gels with appropriate percentage (8-10% for PLD1)

  • Consider Phos-tag™ acrylamide for enhanced separation of phosphorylated species

• Transfer and blocking:

  • Use PVDF membrane for higher protein binding capacity

  • Block with 5% BSA in TBST rather than milk (milk contains casein phosphoproteins)

  • Include phosphatase inhibitors in washing and blocking buffers

• Antibody incubation:

  • Use recommended dilutions (1:500-1:2000)

  • Incubate at 4°C overnight for optimal sensitivity

  • Use phospho-specific antibody first when stripping and reprobing

• Signal development:

  • Consider enhanced chemiluminescence or fluorescent detection systems

  • Validate results with multiple exposure times

These optimizations enhance detection sensitivity while maintaining specificity for the phosphorylated form of PLD1.

How can researchers distinguish between PKC-mediated and RSK2-mediated phosphorylation of PLD1 at T147?

The T147 site in PLD1 can be phosphorylated by multiple kinases, and distinguishing between them requires specific experimental approaches:

Research has demonstrated that in neuroendocrine cells, RSK2 appears to be the predominant kinase responsible for T147 phosphorylation during calcium-regulated exocytosis . This represents an important shift from the traditional view that PKC was the primary kinase for this site.

What is the relationship between T147 phosphorylation and PLD1 activation during exocytosis?

PLD1 activation during exocytosis involves a complex sequence of events where T147 phosphorylation plays a crucial role:

• In neuroendocrine cells, PLD1 is activated in response to secretagogues to produce phosphatidic acid (PA) at granule docking sites on the plasma membrane .

• T147 phosphorylation increases significantly in cells stimulated with potassium (K+), correlating with increased PLD activity .

• Experimental evidence demonstrates that:

  • Phosphorylation-deficient mutant (T147A) fails to restore normal PLD activity and secretion in stimulated cells

  • Phospho-mimetic mutants (T147D and T147E) enhance PLD1 activation and secretion

• RSK2 physically interacts with PLD1 and phosphorylates T147 in cells undergoing exocytosis, with RSK2 depletion dramatically reducing T147 phosphorylation and subsequent PLD activity .

This mechanistic pathway represents an essential regulatory circuit for the late stages of exocytosis, connecting extracellular signals to localized PA production required for membrane fusion events.

How do PLD1 inhibitors interact with the T147 phosphorylation site?

While the search results don't directly address inhibitor interaction with the T147 site specifically, they provide valuable context on PLD inhibition mechanisms:

Researchers studying PLD1 inhibitors should consider:

• Whether T147 phosphorylation alters inhibitor binding affinity or efficacy

• If inhibitors differentially affect phosphorylated versus non-phosphorylated PLD1

• The potential for developing inhibitors that specifically target phospho-conformations of PLD1

What are the known differences in T147 phosphorylation patterns between normal and pathological conditions?

The search results provide intriguing connections between PLD1 T147 phosphorylation and disease states, particularly through the RSK2 kinase:

RSK2 mutations are associated with Coffin-Lowry syndrome, characterized by intellectual disability, distinctive facial features, and skeletal abnormalities . Given that RSK2 is a primary kinase for PLD1 T147 phosphorylation in neuroendocrine cells, this suggests potential dysregulation of PLD1 activity in this syndrome.

Additional pathological connections may include:

• Altered exocytosis in neurodegenerative conditions

• Potential implications in cancer, as PLD1 is involved in cellular proliferation pathways

• Possible roles in metabolic disorders through disruption of secretory processes

How should researchers design experiments to study the functional consequences of T147 phosphorylation?

To investigate the functional significance of T147 phosphorylation, researchers should consider comprehensive experimental approaches:

• Genetic approaches:

  • Express phosphorylation-deficient (T147A) and phospho-mimetic (T147D/E) PLD1 mutants in appropriate cell systems

  • Use siRNA knockdown of endogenous PLD1 followed by rescue with mutant constructs

  • Consider CRISPR/Cas9 genome editing for endogenous mutation of T147

• Functional readouts:

  • Measure PLD enzymatic activity using established assays

  • Assess cellular processes known to involve PLD1 (e.g., exocytosis, membrane trafficking)

  • For secretory cells, measure regulated secretion (e.g., growth hormone release)

• Temporal dynamics:

  • Utilize phospho-specific antibodies to track T147 phosphorylation kinetics

  • Correlate phosphorylation timing with functional outcomes

  • Consider rapid techniques like FRET-based sensors for real-time monitoring

• Pathway integration:

  • Manipulate upstream kinases (RSK2, PKC) to alter T147 phosphorylation

  • Investigate cross-talk with other PLD1 regulatory mechanisms

  • Assess downstream effectors of PLD1-generated phosphatidic acid

These approaches collectively provide mechanistic insights into how T147 phosphorylation regulates PLD1 function across different cellular contexts.

What methodological challenges exist when working with phospho-specific antibodies for PLD1?

Researchers face several methodological challenges when working with phospho-specific antibodies:

• Signal specificity:

  • Cross-reactivity with non-phosphorylated PLD1 or related proteins

  • Potential recognition of similar phosphorylation motifs in other proteins

  • Limited sensitivity for detecting low-abundance phosphorylated forms

• Sample preparation hurdles:

  • Rapid dephosphorylation during sample processing

  • Need for comprehensive phosphatase inhibitor cocktails

  • Maintaining phosphorylation status throughout experimental procedures

• Context-dependent phosphorylation:

  • Cellular heterogeneity in phosphorylation status

  • Temporal dynamics requiring precise experimental timing

  • Cell type-specific phosphorylation patterns

• Technical considerations:

  • Optimizing antibody concentration and incubation conditions

  • Selecting appropriate blocking agents (avoiding milk proteins)

  • Determining ideal detection systems for sensitivity/specificity balance

Addressing these challenges requires rigorous control experiments, method optimization, and careful interpretation of results when using phospho-specific antibodies for PLD1.

How can mass spectrometry complement antibody-based detection of T147 phosphorylation?

Mass spectrometry (MS) provides powerful complementary approaches to antibody-based detection:

• Unbiased phosphorylation site mapping:

  • Identifies all phosphorylation sites on PLD1 simultaneously

  • Discovers novel sites and their relationship to T147

  • Quantifies relative abundance of different phosphorylated forms

• Quantitative analysis:

  • Absolute quantification of phosphorylation stoichiometry

  • Relative changes across experimental conditions

  • Correlation with functional outcomes

• Phosphorylation dynamics:

  • Temporal profiling of phosphorylation/dephosphorylation cycles

  • Identification of sequential phosphorylation events

  • Integration with other post-translational modifications

• Sample preparation considerations:

  • Enrichment of phosphopeptides using TiO2 or IMAC

  • Use of phosphatase inhibitors during sample processing

  • Consideration of protein extraction methods to maintain modifications

• Data analysis:

  • Sophisticated software for phosphopeptide identification

  • Statistical approaches for quantification

  • Pathway analysis to integrate findings

MS approaches can validate antibody specificity while providing additional layers of information about the phosphorylation status of PLD1 in complex biological samples.

What are the emerging questions regarding PLD1 T147 phosphorylation in different cellular contexts?

Several frontier research questions emerge from our current understanding:

• Cell type-specific regulation:

  • How does T147 phosphorylation vary across different cell types and tissues?

  • Are different kinases responsible for T147 phosphorylation in non-neuroendocrine cells?

  • How is phosphorylation integrated with other regulatory mechanisms?

• Signaling network integration:

  • How does T147 phosphorylation coordinate with other PLD1 phosphorylation sites?

  • What is the interplay between different kinases (RSK2, PKC) in determining phosphorylation patterns?

  • How does phosphorylation affect PLD1 interaction with small GTPases and other regulatory proteins?

• Structural implications:

  • How does T147 phosphorylation alter PLD1 conformation and activity?

  • Does phosphorylation affect protein-protein interactions or subcellular localization?

  • Can structural insights lead to phosphorylation-state specific inhibitors?

• Pathological relevance:

  • Is T147 phosphorylation dysregulated in specific diseases?

  • Does altered phosphorylation contribute to disease mechanisms?

  • Can targeting this phosphorylation site offer therapeutic potential?

These questions represent important areas for future investigation that will enhance our understanding of PLD1 regulation and function.

How might new phospho-proteomic technologies advance our understanding of PLD1 regulation?

Emerging technologies offer exciting possibilities for studying PLD1 phosphorylation:

• Single-cell phosphoproteomics:

  • Reveals cell-to-cell heterogeneity in phosphorylation states

  • Identifies rare cell populations with unique phosphorylation patterns

  • Tracks phosphorylation dynamics during cell state transitions

• Proximity labeling approaches:

  • BioID or TurboID fusions to identify proteins near phosphorylated PLD1

  • Mapping phosphorylation-dependent interaction networks

  • Spatial context for phosphorylation events

• Advanced imaging techniques:

  • Super-resolution microscopy of phosphorylated PLD1 localization

  • FRET-based sensors for real-time phosphorylation monitoring

  • Correlative light and electron microscopy for ultrastructural context

• Integrative multi-omics:

  • Combining phosphoproteomics with transcriptomics and metabolomics

  • Systems biology approaches to model phosphorylation networks

  • Machine learning to predict phosphorylation consequences

These technologies promise to provide unprecedented insights into the spatiotemporal dynamics and functional significance of PLD1 phosphorylation in diverse biological contexts.